While the Buy rating reaffirms confidence in ACADIA Pharmaceuticals' long-term prospects, the reduction in price target may reflect adjustments in valuation expectations, possibly due to market conditions or company performance. This mixed signal could lead to short-term price volatility as investors reassess their expectations.